Metelimumab Biosimilar – Anti-TGFB1 mAb – Research Grade

Description of Metelimumab Biosimilar - Anti-TGFB1 mAb - Research Grade

Introduction

Metelimumab Biosimilar, also known as anti-TGFB1 mAb, is a research grade antibody that targets the protein transforming growth factor beta 1 (TGFB1). This antibody is being developed as a potential therapeutic option for various diseases and conditions related to TGFB1 dysregulation. In this article, we will explore the structure, activity, and potential applications of Metelimumab Biosimilar.

Structure of Metelimumab Biosimilar

Metelimumab Biosimilar is a monoclonal antibody, meaning it is produced from a single type of immune cell. It is a humanized antibody, which means it is derived from non-human sources but has been modified to be more similar to human antibodies. This allows for better compatibility and reduced risk of immune reactions in patients.

The antibody is composed of two heavy chains and two light chains, which are connected by disulfide bonds. It has a molecular weight of approximately 150 kDa. Metelimumab Biosimilar specifically binds to the active form of TGFB1, preventing it from interacting with its receptors and exerting its effects.

Activity of Metelimumab Biosimilar

TGFB1 is a multifunctional cytokine that plays a crucial role in various physiological processes, including cell growth, differentiation, and immune response. However, dysregulation of TGFB1 has been linked to the development and progression of many diseases, including cancer, fibrosis, and autoimmune disorders.

Metelimumab Biosimilar works by specifically binding to TGFB1 and inhibiting its activity. This prevents TGFB1 from promoting inflammation, fibrosis, and other pathological processes. By targeting the active form of TGFB1, Metelimumab Biosimilar has the potential to treat a wide range of diseases and conditions associated with TGFB1 dysregulation.

Potential Applications of Metelimumab Biosimilar

As mentioned earlier, Metelimumab Biosimilar has the potential to be used as a therapeutic option for various diseases and conditions related to TGFB1 dysregulation. Some of the potential applications of this antibody include:

Cancer TGFB1 has been shown to promote tumor growth and metastasis in various types of cancer. By inhibiting TGFB1 activity, Metelimumab Biosimilar could potentially slow down tumor growth and prevent its spread to other parts of the body. This antibody could also be used in combination with other cancer treatments to enhance their effectiveness.

Fibrosis

Fibrosis is a condition characterized by the excessive accumulation of scar tissue in organs. TGFB1 is a major contributor to the development of fibrosis, and its inhibition by Metelimumab Biosimilar could potentially slow down or even reverse the progression of this condition.

Autoimmune Disorders

In autoimmune disorders, the immune system mistakenly attacks healthy tissues in the body. TGFB1 has been shown to play a role in the development and maintenance of autoimmune responses. By inhibiting TGFB1 activity, Metelimumab Biosimilar could potentially reduce the severity of autoimmune disorders and improve patient outcomes.

Other Potential Applications

Besides the above-mentioned conditions, Metelimumab Biosimilar could also have potential applications in other diseases and conditions, such as pulmonary fibrosis, diabetic nephropathy, and inflammatory bowel disease. Further research and clinical trials are needed to explore the full potential of this antibody.

Conclusion

In conclusion, Metelimumab Biosimilar is a research grade antibody that specifically targets the active form of TGFB1. By inhibiting TGFB1 activity, this antibody has the potential to treat a wide range of diseases and conditions related to TGFB1 dysregulation. With ongoing research and development, Metelimumab Biosimilar could potentially become a valuable therapeutic option for patients in the future.

Metelimumab Biosimilar - Anti-TGFB1 mAb binds to Human TGFB1/TGF-beta-1 in indirect ELISA Assay

Immobilized TGFB1 recombinant protein (cat. No. PX-P5187) at 0.5µg/mL (100µL/well) can bind Metelimumab Biosimilar - Anti-TGFB1 mAb (cat. No. PX-TA1138) in indirect ELISA with Goat Anti-Human IgG secondary antibody coupled with HRP measured by OD450 giving an EC50 at 133.8M.